Industry Advocacy

Savings from biosimilar medicines alone increased to $12.4 billion in 2023 and $36 billion since the first biosimilar entry in 2015, according to AAM's latest report.

Discussions centered around the soaring DIR Fees and the dominance of major PBMs in the market.

The U.S. Federal Trade Commission’s lawsuit to block Kroger-Albertson’s merger went to trial today in federal court in Portland, Ore.

The Biosimilars Council agrees with the FDA's position that data from a switching study or studies may no longer be necessary to support licensure of interchangeable biosimilar medicines.

The ERISA Industry Committee calls the effort to update interchangeability guidance a positive step.

Kroger is suing the FTC, seeking to block the agency from reviewing its proposed merger with Albertsons.

According to a report, the grocer intends to double its proposed price cuts upon the completion of the $25.6 billion deal.

The way pharmacies are paid for medications is an antiquated model and ignorant of the vital role of the pharmacist, Anderson said.